[1]
|
Sugano, K., Tack, J., Kuipers, E.J., et al. (2015) Kyoto Global Consensus Report on Helicobacter pylori Gastritis. Gut, 64, 1353-1367. https://doi.org/10.1136/gutjnl-2015-309252
|
[2]
|
Malfertheiner, P., Megraud, F., O’Morain, C.A., et al. (2017) Management of Helicobacter pylori Infection—The Maastricht V/Florence Consensus Report. Gut, 66, 6-30. https://doi.org/10.1136/gutjnl-2016-312288
|
[3]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[4]
|
李兆申, 吕农华, 周丽雅. 中国幽门螺杆菌根除与胃癌防控的专家共识意见(2019年, 上海) [J]. 中华健康管理学杂志, 2019, 13(4): 285-291.
|
[5]
|
Burucoa, C. and Axon, A. (2017) Epidemiology of Helicobacter pylori Infection. Helicobacter, 22, e12403.
https://doi.org/10.1111/hel.12403
|
[6]
|
刘文忠, 等. 第五次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学, 2017, 22(6): 346-360.
|
[7]
|
文学琴, 谷俊莹, 陈峥宏. 幽门螺杆菌对四环素耐药的机制研究进展[J]. 中国抗生素杂志, 2020, 45(6): 545-550.
|
[8]
|
Zhang, L., Lan, Y., Wang, Q., et al. (2019) Application of Minocycline-Containing Bismuth Quadruple Therapies as First-Line Regimens in the Treatment of Helicobacter pylori. Gastroenterology Research and Practice, 2019, Article ID: 9251879. https://doi.org/10.1155/2019/9251879
|
[9]
|
徐淑兰, 洪卫康, 宣世海. 含米诺环素的四联治疗方案作为一线和二线方案根治幽门螺杆菌感染的研究[J]. 现代消化及介入诊疗, 2019, 24(10): 1133-1136.
|
[10]
|
蒲宁, 卡世会, 汤志刚. 雷贝拉唑/米诺环素/阿莫西林/铋剂方案作为一、二线方案根除幽门螺杆菌的疗效[J]. 中国老年学杂志, 2018, 38(23): 5713-5715.
|
[11]
|
Graham, D.Y. and Dore, M.P. (2016) Helicobacter pylori Therapy: A Paradigm Shift. Expert Review of Anti-Infective Therapy, 14, 577-585. https://doi.org/10.1080/14787210.2016.1178065
|
[12]
|
Savoldi, A., Carrara, E., Graham, D.Y., et al. (2018) Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-Analysis in World Health Organization Regions. Gastroenterology, 155, 1372-1382.
https://doi.org/10.1053/j.gastro.2018.07.007
|
[13]
|
Murakami, K., Sato, R., Okimoto, T., et al. (2006) Effectiveness of Minocycline-Based Triple Therapy for Eradication of Helicobacter pylori Infection. Gastroenterology & Hepatology, 21, 262-267.
https://doi.org/10.1111/j.1440-1746.2006.04183.x
|
[14]
|
Song, Z.Q. and Zhou, L.Y. (2016) Esomeprazole, Minocycline, Metronidazole and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication. Digital Distribution, 17, 260-267.
https://doi.org/10.1111/1751-2980.12334
|
[15]
|
Song, Z., Suo, B., Zhang, L., et al. (2016) Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication. Helicobacter, 21, 462-470.
https://doi.org/10.1111/hel.12313
|
[16]
|
Ierardi, E., Giangaspero, A., Losurdo, G., et al. (2014) Quadruple Rescue Therapy after First and Second Line Failure for Helicobacter pylori Treatment: Comparison between Two Tetracycline-Based Regimens. Journal of Gastrointestinal and Liver Diseases, 23, 367-370. https://doi.org/10.15403/jgld.2014.1121.234.qrth
|
[17]
|
Nakajima, S., Inoue, H., Inoue, T., et al. (2012) Multiple-Antibiotic-Resistant Helicobacter pylori Infection Eradicated with a Tailor-Made Quadruple Therapy. Gastroenterology & Hepatology, 27, 108-111.
https://doi.org/10.1111/j.1440-1746.2012.07069.x
|
[18]
|
李梦迪, 王梓楠, 郑松柏. 含利福布汀 + 呋喃唑酮的三联方案与含米诺环素 + 呋喃唑酮的四联方案根除难治性幽门螺杆菌感染的疗效和安全性[J]. 中华消化杂志, 2019, 2019(12): 812-816.
|